Patents by Inventor Holger Rosenbrock
Holger Rosenbrock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101689Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: November 28, 2023Publication date: March 28, 2024Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
-
Patent number: 11866501Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: August 26, 2020Date of Patent: January 9, 2024Assignee: Boehringer Ingelheim International GmbHInventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Katharina Florin, Cynthia Hess Kenny, Sarah Kathleen Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir H. Voynov, Haiguang Xiao
-
Publication number: 20220047562Abstract: The invention relates to the treatment of cognitive impairment associated with schizophrenia (CIAS) with a specific GlyT1 inhibitor ([5-(methylsulfonyl)-2-{[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone). A 12-week treatment in a phase 2 study showed improvement in cognitive function as measured by the MATRICS Consensus Cognitive Battery (MCCB) overall composite score.Type: ApplicationFiled: August 11, 2021Publication date: February 17, 2022Inventors: Jana PODHORNA, Holger ROSENBROCK, Sunyong YUM, Yihua ZHAO
-
Publication number: 20210130362Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.Type: ApplicationFiled: January 11, 2021Publication date: May 6, 2021Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
-
Patent number: 10919898Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.Type: GrantFiled: February 21, 2018Date of Patent: February 16, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
-
Publication number: 20200399378Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: August 26, 2020Publication date: December 24, 2020Inventors: Rolf HERRMANN, Remko Alexander BAKKER, Sebastian BANDHOLTZ, Peter Michael BENZ, Michael DZIEGELEWSKI, Lore Katharina FLORIN, Cynthia Hess KENNY, Sarah Kathleen LOW, Holger ROSENBROCK, Sanjaya SINGH, Heiko Friedrich STAHL, Sathyadevi VENKATARAMANI, Vladimir H. VOYNOV, Haiguang XIAO
-
Patent number: 10793634Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: GrantFiled: June 7, 2018Date of Patent: October 6, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
-
Publication number: 20180355046Abstract: The present invention relates to novel agonistic anti-TrkB antibodies and therapeutic and diagnostic methods and compositions for using the same.Type: ApplicationFiled: June 7, 2018Publication date: December 13, 2018Inventors: Rolf Herrmann, Remko Alexander Bakker, Sebastian Bandholtz, Peter Michael Benz, Michael Dziegelewski, Lore Florin, Cynthia Hess Kenny, Sarah Low, Holger Rosenbrock, Sanjaya Singh, Heiko Friedrich Stahl, Sathyadevi Venkataramani, Vladimir Voynov, Haiguang Xiao
-
Publication number: 20180237445Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.Type: ApplicationFiled: February 21, 2018Publication date: August 23, 2018Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
-
Patent number: 9328120Abstract: The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.Type: GrantFiled: October 10, 2014Date of Patent: May 3, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Niklas Heine, Christian Eickmeier, Marco Ferrera, Riccardo Giovannini, Holger Rosenbrock, Gerhard Schaenzle
-
Patent number: 9233953Abstract: The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).Type: GrantFiled: October 14, 2014Date of Patent: January 12, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Christoph Hoenke, Riccardo Giovannini, Uta Lessel, Holger Rosenbrock, Bernhard Schmid
-
Patent number: 9102679Abstract: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R1 is the group V—W—*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.Type: GrantFiled: November 22, 2013Date of Patent: August 11, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Riccardo Giovannini, Cornelia Dornier-Ciossek, Christian Eickmeier, Dennis Fiegen, Thomas Fox, Klaus Fuchs, Niklas Heine, Holger Rosenbrock, Gerhard Schaenzle
-
Patent number: 9096603Abstract: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.Type: GrantFiled: November 12, 2013Date of Patent: August 4, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Riccardo Giovannini, Cornelia Dorner-Ciossek, Christian Eickmeier, Dennis Fiegen, Thomas Fox, Klaus Fuchs, Niklas Heine, Holger Rosenbrock, Gerhard Schaenzle
-
Patent number: 9079905Abstract: The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I). wherein A, R1-R5 and x are as defined herein, and their use as medicaments for improving perception, concentration, learning and/or memory in patients in need thereof.Type: GrantFiled: September 4, 2009Date of Patent: July 14, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Klaus Fuchs, Cornelia Dorner-Ciossek, Christian Eickmeier, Dennis Fiegen, Thomas Fox, Riccardo Giovannini, Niklas Heine, Martin Hendrix, Holger Rosenbrock, Gerhard Schaenzle
-
Patent number: 9012489Abstract: Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders.Type: GrantFiled: July 27, 2012Date of Patent: April 21, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Riccardo Giovannini, Barbara Bertani, Marco Ferrara, Iain Lingard, Rocco Mazzaferro, Holger Rosenbrock
-
Publication number: 20150105397Abstract: The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).Type: ApplicationFiled: October 14, 2014Publication date: April 16, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Christoph HOENKE, Riccardo GIOVANNINI, Uta LESSEL, Holger ROSENBROCK, Bernhard SCHMID
-
Publication number: 20150025088Abstract: The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I). wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2. The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.Type: ApplicationFiled: October 10, 2014Publication date: January 22, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Niklas HEINE, Christian EICKMEIER, Marco FERRERA, Riccardo GIOVANNINI, Holger ROSENBROCK, Gerhard SCHAENZLE
-
Patent number: 8912201Abstract: The invention relates to novel 6-cycloalkyl-pyrazolopyrimidinones according to formula (I) wherein R1, R2, D, m and n are as defined herein. The invention also relates to medicaments comprising these compounds and methods of using these compounds in the treatment of diseases and conditions, particularly diseases or conditions concerning deficits in perception, concentration, learning or memory.Type: GrantFiled: August 10, 2011Date of Patent: December 16, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Niklas Heine, Christian Eickmeier, Marco Ferrara, Riccardo Giovannini, Holger Rosenbrock, Gerhard Schaenzle
-
Publication number: 20140350025Abstract: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I), in which Hc is a tetrahydropyranyl-group and R1 is the group V—W—*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted. According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.Type: ApplicationFiled: November 22, 2013Publication date: November 27, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Riccardo GIOVANNINI, Cornelia DORNER-CIOSSEK, Christian EICKMEIER, Dennis FIEGEN, Thomas FOX, Klaus FUCHS, Niklas HEINE, Holger ROSENBROCK, Gerhard SCHAENZLE
-
Publication number: 20140073641Abstract: The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, wherein i.) the nitrogen atom of the pyrazolo-group that is next to the pyrimidino-group is attached to a non-aromatic, organic heterocycle having at least one ring hetero atom selected from O, N and S and ii.) to the C-atom between the two nitrogen atoms of the pyrimidinone-ring a second substituent is bound via an optionally substituted methylene-bridge. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.Type: ApplicationFiled: November 12, 2013Publication date: March 13, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Riccardo GIOVANNINI, Cornelia DORNER-CIOSSEK, Christian EICKMEIER, Dennis FIEGEN, Thomas FOX, Klaus FUCHS, Niklas HEINE, Holger ROSENBROCK, Gerhard SCHAENZLE